Is Pfizer a Buy After Recent Deals and Pricing Agreements?

Audience asks about Pfizer; Cramer argues Pfizer lacks a growth engine and remains low multiple and uninvestable for now.

Play episode from 30:13

Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!